Establishment and Evaluation of a Mouse Model of Experimental Ulcerative Colitis Induced by the Gavage Administration of Dextran Sulfate Sodium
-
Published:2024-08-05
Issue:8
Volume:12
Page:1764
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Wang Dan1, Chen Wei1, Cao Jie1, Si Luqin2, Chen Zehong1
Affiliation:
1. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China 2. Department of Pharmaceutics, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China
Abstract
Given the critical role of dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) mouse models in the appraisal of associated therapeutic drugs, the optimization of the administration method and dosages is of paramount importance. Therefore, UC was induced in mice through the gavage administration of a DSS solution instead of free drinking water. The effects of varying daily dosages (2, 4, 6, and 8 g/kg) and frequencies (once or twice) of administration on the body weight and survival rate of the model mice were evaluated. Concurrently, the inflammatory indicators and tissue sections of the model mice were thoroughly evaluated. The results revealed that when the daily dosage reached 8 g/kg, the dosage exhibited a high level of toxicity, resulting in a high mortality rate among the mice. The DSS administration of 6 g/kg*2 not only elicited conspicuous symptoms, significant weight loss, substantial shortening of the colon, and significant changes in various inflammatory indicators, such as myeloperoxidase (MPO), nitric oxide (NO), reactive oxygen species (ROS), and glutathione (GSH), but it also maintained a high survival rate in the UC mice. The findings from this experiment lay a solid experimental foundation for future research on drugs intended for the treatment of UC.
Reference39 articles.
1. Jadhav, A., Jagtap, S., Vyavahare, S., Sharbidre, A., and Kunchiraman, B. (2023). Reviewing the potential of probiotics, prebiotics and synbiotics: Advancements in treatment of ulcerative colitis. Front. Cell Infect. Microbiol., 13. 2. Ulcerative Colitis in Adults: A Review;Gros;JAMA,2023 3. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies;Ng;Lancet,2017 4. Sato, Y., Tsujinaka, S., Miura, T., Kitamura, Y., Suzuki, H., and Shibata, C. (2023). Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management. Cancers, 15. 5. Chen, K., Shang, S., Yu, S., Cui, L., Li, S., and He, N. (2022). Identification and exploration of pharmacological pyroptosis-related biomarkers of ulcerative colitis. Front. Immunol., 13.
|
|